Lucid Diagnostics (LUCD) News Today $1.55 +0.05 (+3.33%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$1.53 -0.02 (-1.29%) As of 03/25/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Lucid Diagnostics Inc. (LUCD) Q4 2024 Earnings Call TranscriptMarch 26 at 3:44 AM | seekingalpha.comLucid Diagnostics (NASDAQ:LUCD) Stock Price Expected to Rise, Needham & Company LLC Analyst SaysMarch 26 at 1:59 AM | americanbankingnews.comLucid Diagnostics Earnings Call Highlights Growth and ChallengesMarch 25 at 8:15 PM | tipranks.comLucid Diagnostics (NASDAQ:LUCD) Given New $3.00 Price Target at Needham & Company LLCNeedham & Company LLC increased their price objective on shares of Lucid Diagnostics from $2.50 to $3.00 and gave the company a "buy" rating in a research note on Monday.March 25 at 3:01 PM | marketbeat.comLucid Diagnostics (NASDAQ:LUCD) Issues Earnings Results, Misses Expectations By $0.06 EPSLucid Diagnostics (NASDAQ:LUCD - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.06).March 25 at 9:53 AM | marketbeat.comLucid Diagnostics Inc. (NASDAQ:LUCD) Q4 2024 Earnings Call TranscriptMarch 25 at 9:20 AM | insidermonkey.comLucid Diagnostics reports Q4 EPS (19c) vs (23c) last yearMarch 24 at 11:29 PM | markets.businessinsider.comComparing Beauty Health (NASDAQ:SKIN) & Lucid Diagnostics (NASDAQ:LUCD)March 24 at 1:53 AM | americanbankingnews.comLucid Diagnostics Inc (LUCD) Q4 2024 Earnings Report Preview: What To ExpectMarch 22, 2025 | finance.yahoo.comNeedham maintains Buy on Lucid Diagnostics, $2.50 targetMarch 22, 2025 | uk.investing.comLucid Diagnostics (LUCD) to Release Quarterly Earnings on MondayMarch 22, 2025 | americanbankingnews.comLucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer ScreeningMarch 20, 2025 | prnewswire.comBTIG Keeps Their Buy Rating on Lucid Diagnostics (LUCD)March 18, 2025 | markets.businessinsider.comLucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed PublicationMarch 18, 2025 | prnewswire.comLucid Diagnostics (LUCD) Expected to Announce Earnings on MondayLucid Diagnostics (NASDAQ:LUCD) will be releasing earnings before the market opens on Monday, March 24, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=673713)March 17, 2025 | marketbeat.comShort Interest in Lucid Diagnostics Inc. (NASDAQ:LUCD) Rises By 72.1%Lucid Diagnostics Inc. (NASDAQ:LUCD - Get Free Report) saw a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 1,790,000 shares, a growth of 72.1% from the February 13th total of 1,040,000 shares. Based on an average daily trading volume, of 576,100 shares, the days-to-cover ratio is presently 3.1 days. Currently, 5.6% of the company's shares are sold short.March 16, 2025 | marketbeat.comLucid Diagnostics secures first positive insurance coverage for EsoGuard testMarch 13, 2025 | markets.businessinsider.comLucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA TestMarch 13, 2025 | prnewswire.comLucid Diagnostics (NASDAQ:LUCD) Trading Down 14.4% - Here's WhyLucid Diagnostics (NASDAQ:LUCD) Trading Down 14.4% - Time to Sell?March 11, 2025 | marketbeat.comLucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025March 10, 2025 | prnewswire.comLucid Diagnostics Announces Closing of $15.3 Million Registered Direct OfferingMarch 5, 2025 | prnewswire.comLucid Diagnostics stock dips on $15.3M share offeringMarch 4, 2025 | msn.comLucid Diagnostics Announces $15.3 Million Registered Direct OfferingMarch 4, 2025 | prnewswire.comLucid Diagnostics Inc. (NASDAQ:LUCD) Sees Significant Increase in Short InterestLucid Diagnostics Inc. (NASDAQ:LUCD - Get Free Report) was the recipient of a large growth in short interest in February. As of February 15th, there was short interest totalling 1,040,000 shares, a growth of 95.2% from the January 31st total of 532,700 shares. Based on an average trading volume of 531,800 shares, the days-to-cover ratio is presently 2.0 days. Currently, 4.3% of the company's stock are short sold.March 2, 2025 | marketbeat.comRenowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard in At-Risk Patients without Symptomatic GERDFebruary 28, 2025 | finanznachrichten.deRenowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERDFebruary 27, 2025 | prnewswire.comLucid Diagnostics regains Nasdaq complianceFebruary 26, 2025 | markets.businessinsider.comLucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price RequirementFebruary 25, 2025 | prnewswire.comLucid Diagnostics entered first concierge medicine contract with LEAA HealthFebruary 20, 2025 | markets.businessinsider.comLucid Diagnostics Executes First Concierge Medicine Contract with LEAA HealthFebruary 20, 2025 | prnewswire.comLucid Diagnostics stock hits 52-week high at $1.5 amid growth optimismFebruary 14, 2025 | msn.comLucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceFebruary 6, 2025 | prnewswire.comSargent Investment Group LLC Takes $442,000 Position in Lucid Diagnostics Inc. (NASDAQ:LUCD)Sargent Investment Group LLC acquired a new stake in shares of Lucid Diagnostics Inc. (NASDAQ:LUCD - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 541,500 shares of the companyFebruary 6, 2025 | marketbeat.comLucid Diagnostics (NASDAQ:LUCD) Stock Price Down 0.5% - Here's What HappenedLucid Diagnostics (NASDAQ:LUCD) Stock Price Down 0.5% - Here's WhyJanuary 21, 2025 | marketbeat.comLucid Diagnostics reports record quarterly EsoGuard test volumeJanuary 14, 2025 | markets.businessinsider.comLucid Diagnostics Announces Record Quarterly EsoGuard Test VolumeJanuary 13, 2025 | finanznachrichten.deLucid Diagnostics Announces Record Quarterly EsoGuard® Test VolumeJanuary 13, 2025 | prnewswire.comLucid Gains Extension of Compliance by NASDAQDecember 23, 2024 | baystreet.caLucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RuleDecember 23, 2024 | finance.yahoo.comLucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for FirefightersDecember 19, 2024 | prnewswire.comProspective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed PublicationDecember 11, 2024 | prnewswire.comLucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term MilestonesDecember 3, 2024 | prnewswire.comLucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest Down 30.6% in NovemberLucid Diagnostics Inc. (NASDAQ:LUCD - Get Free Report) was the recipient of a large decrease in short interest in November. As of November 15th, there was short interest totalling 293,100 shares, a decrease of 30.6% from the October 31st total of 422,400 shares. Based on an average daily volume of 319,300 shares, the short-interest ratio is currently 0.9 days. Approximately 1.5% of the company's stock are sold short.November 29, 2024 | marketbeat.comLucid Diagnostics’ Strategic Financial Maneuvering and AgreementsNovember 29, 2024 | tipranks.comLucid Diagnostics submits clinical evidence for EsoGuard Esophagea DNA testNovember 21, 2024 | markets.businessinsider.comLucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA TestNovember 20, 2024 | prnewswire.comLucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumNovember 18, 2024 | prnewswire.comLucid Diagnostics: Strong Growth Potential Justifies Buy RatingNovember 15, 2024 | markets.businessinsider.comLucid Diagnostics: Buy Rating Affirmed on Strong Revenue Growth and Future Expansion PotentialNovember 15, 2024 | markets.businessinsider.comLucid Diagnostics (NASDAQ:LUCD) Price Target Cut to $2.00 by Analysts at Cantor FitzgeraldCantor Fitzgerald decreased their target price on Lucid Diagnostics from $3.00 to $2.00 and set an "overweight" rating for the company in a report on Friday.November 15, 2024 | marketbeat.com Remove Ads Get Lucid Diagnostics News Delivered to You Automatically Sign up to receive the latest news and ratings for LUCD and its competitors with MarketBeat's FREE daily newsletter. Email Address LUCD Media Mentions By Week LUCD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LUCD News Sentiment▼0.170.79▲Average Medical News Sentiment LUCD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LUCD Articles This Week▼152▲LUCD Articles Average Week Remove Ads Get Lucid Diagnostics News Delivered to You Automatically Sign up to receive the latest news and ratings for LUCD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SMLR News ZIMV News NNOX News TCMD News LUNG News CVRX News SMTI News AVR News RCEL News NVRO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LUCD) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lucid Diagnostics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lucid Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
